BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Sintilimab: trial readouts and FDA decisions

0 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, TJ Biopharma Co., Ltd., Fujian Haixi Pharmaceuticals Co., Ltd., Hutchmed, Akeso. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Advanced Hepatocellular Carcinomarecruiting590
2026-09-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNon-Small Cell Lung Canceractive not recruiting506
2026-09 est.P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06558227 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular Carcinomaunknown90
2026-08-30 est.P2TJ Biopharma Co., Ltd.NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated LocaNon Small Cell Lung Canceractive not recruiting150
2026-08-30 est.P1/P2Fujian Haixi Pharmaceuticals Co., Ltd.NCT06220318 Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid TumorsSolid Tumoractive not recruiting155
2026-08-28P2/P3Hutchmed HCMNCT05522231 Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Advanced Renal Cell Carcinomacompleted265
2026-06 est.P1/P2AkesoNCT06530251 A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)Hepatocellular Carcinomarecruiting280

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.